Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesTRACON Pharmaceuticals Inc

TRACON Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
None USD 0.00(0%)
Last update at 2026-11-10T21:09:19.133390Z
Market Cap
0.11M
P/E
0.01

Momentum Score

…

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

52 Week Price Range
16.31
Low
17.59
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

TRACON Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing therapeutics in oncology and ophthalmology. Long-term growth may be driven by clinical trial progress, regulatory milestones, licensing or partnership agreements and eventual product commercialization, and investors may find the company attractive for its focused pipeline and potential milestone-driven upside.
Principal risks include the high probability of clinical or regulatory setbacks, ongoing capital requirements that could dilute shareholders, limited trading liquidity on the OTCQB, and strong competitive and intellectual property pressures.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
17.46
Dividend Yield
-
Revenue TTM
3.20M
Revenue Per Share
1.41
Gross Profit TTM
-8.91M
Debt / Equity
-1.20
ROE
-1277.01%
Net Debt
-7.60M
ROCE
8958.44%
Diluted EPS TTM
5.93

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -3.59M -29.14M -28.67M -16.77M -22.67M
Net income -3.59M -29.31M -28.73M -17.33M -22.66M
Selling general administrative 6.67M 14.01M 17.55M 8.03M 7.77M
Gross profit 12.03M - 0.35M - -14.53M
Reconciled depreciation 0.04M 0.07M -0.06M -0.01M 0.02M
Ebit -6.90M -27.96M -28.29M -16.22M -22.31M
Ebitda -6.88M -27.89M -28.35M -16.23M -22.30M
Depreciation and amortization 0.01M 0.07M -0.06M -0.01M 0.02M
Non operating income net other - - - -0.01M 0.01M
Operating income -6.90M -27.89M -28.35M -16.22M -22.30M
Other operating expenses 18.94M 27.89M 28.69M 16.22M 22.30M
Interest expense 7.30M 0.99M 0.32M 0.55M 0.39M
Interest income - - - - 0.39M
Net interest income -8.26M -0.99M -0.32M -0.55M -0.39M
Income tax expense -0.15M 0.18M 0.06M 0.55M -0.02M
Total revenue 12.04M 0.00M 0.35M 0.00M 0.00M
Total operating expenses 18.93M 27.89M 28.69M 16.22M 22.30M
Cost of revenue 0.01M - - - 14.53M
Total other income expense net 3.31M -1.24M -0.32M -0.55M -0.38M
Net income from continuing ops -11.02M -29.14M -28.67M -16.77M -22.67M
Net income applicable to common shares - -29.14M -28.67M -16.77M -22.67M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 10.11M 19.47M 26.56M 37.44M 18.12M
Other current assets 0.53M 0.80M 0.86M 0.78M 0.85M
Total liab 10.91M 26.62M 14.84M 12.37M 15.42M
Total stockholder equity -0.81M -7.15M 11.71M 25.07M 2.70M
Other current liab 7.40M 8.64M 7.34M 5.68M 9.23M
Common stock 0.04M 0.02M 0.02M 0.01M 0.00M
Capital stock 0.04M 0.02M 0.02M 0.01M 0.00M
Retained earnings -240.50M -236.91M -207.78M -179.11M -162.33M
Other liab - 3.28M 1.17M 0.43M 0.28M
Other assets - 0.07M 1.62M 0.51M 0.84M
Cash 8.56M 17.43M 24.07M 32.13M 16.41M
Total current liabilities 10.18M 22.37M 13.68M 10.54M 11.83M
Net debt -7.60M -7.63M -22.68M -27.60M -11.07M
Short term debt 0.24M 9.81M 1.39M 3.14M 2.60M
Short long term debt - 9.81M 1.39M 2.72M 2.60M
Short long term debt total 0.97M 9.81M 1.39M 4.53M 5.34M
Other stockholder equity 239.65M 229.74M 219.47M 204.17M 165.03M
Property plant equipment - 1.17M 0.05M 0.02M 0.02M
Total current assets 9.09M 18.23M 24.94M 36.91M 17.26M
Net tangible assets - -7.15M 11.71M 25.07M 2.70M
Short term investments - - 0.00M 4.00M 0.00M
Long term debt - - - 1.39M 2.74M
Accounts payable 2.54M 3.92M 4.94M 1.73M 1.35M
Accumulated other comprehensive income - - - - -0.15M
Common stock total equity - - - 0.01M 0.00M
Retained earnings total equity - - - -179.11M -162.33M
Non currrent assets other 0.98M 1.19M 1.57M 0.51M 0.84M
Non current assets total 1.01M 1.24M 1.62M 0.52M 0.86M
Capital lease obligations 0.24M 0.20M 0.15M 0.42M -
Long term debt total - - - 1.39M 2.74M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -0.00M -0.02M 4.00M -4.00M 14.02M
Change to liabilities - -0.23M 4.68M 0.23M -0.11M
Total cashflows from investing activities - -0.02M 3.95M -4.00M 14.02M
Net borrowings - 8.28M -2.80M -1.40M -1.40M
Total cash from financing activities -12.54M 19.68M 10.56M 36.76M 0.91M
Change to operating activities - -0.01M -0.14M 0.30M 0.54M
Net income -3.59M -29.14M -28.67M -16.77M -22.67M
Change in cash -8.86M -6.57M -8.06M 15.72M -8.72M
Begin period cash flow 17.50M 24.07M 32.13M 16.41M 25.14M
End period cash flow 8.64M 17.50M 24.07M 32.13M 16.41M
Total cash from operating activities 3.68M -26.24M -22.57M -17.04M -23.65M
Issuance of capital stock 8.06M 7.88M 13.21M 38.16M 2.29M
Depreciation 0.01M 0.07M -0.06M -0.01M 0.02M
Other cashflows from investing activities - - - - 14.02M
Sale purchase of stock - - - - 0.03M
Other cashflows from financing activities 0.04M 13.48M 0.15M 0.00M 0.01M
Change to netincome - 2.68M 1.52M 1.28M 1.86M
Capital expenditures 0.00M 0.02M 0.05M 0.01M 0.01M
Cash flows other operating - - - -1.84M -2.78M
Cash and cash equivalents changes - - - 15.72M -8.72M
Change in working capital -0.76M -0.24M 4.54M -1.58M -2.88M
Stock based compensation 1.97M 2.04M 1.77M 1.03M 1.62M
Other non cash items 6.06M 1.02M -0.16M 0.29M 0.32M
Free cash flow 3.68M -26.26M -22.62M -17.05M -23.65M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
NVO
Novo Nordisk A/S		 -0.68
1.64%		 40.70 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.02
0.55%		 547.85 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 -
-%		 916.06 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

TRACON Pharmaceuticals Inc

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

4350 La Jolla Village Drive, San Diego, CA, United States, 92122

858 550 0780

https://www.traconpharma.com

17

Name Title Year Born
Dr. Charles P. Theuer M.D., Ph.D. CEO, Pres & Director 1964
Mr. Scott B. Brown CPA, M.S. Chief Financial Officer 1981
Ms. Bonne Adams Exec. VP of Clinical Operations 1977
Mr. Shahe Garabedian Sr. VP & Head of Quality Assurance NA
Dr. James L. Freddo Chief Medical Officer 1955
Mr. Ya Huang Exec. Director of Statistical Programming NA
Dr. Brenda Marczi Pharm.D., Pharmd Mba Sr. VP of Regulatory Affairs NA
Dr. Charles P. Theuer M.D., Ph.D. Chairman, CEO & President 1964
Mr. Ya Huang Executive Director of Statistical Programming NA
Mr. Craig R. Jalbert CIRA CEO, President, Treasurer, Secretary & Director 1962

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DRUG
CAD 32.00
+23.08%
CHR
CAD 35.50
+7.80%
HG
CAD 4.77
+7.19%
QTWO
CAD 1.73
+7.14%
PET
CAD 23.03
+7.02%
MUX
CAD 18.80
-17.69%
URE
CAD 0.96
-15.04%
WELL
CAD 3.62
-14.82%
ITH
CAD 2.01
-10.67%
SGML
CAD 7.52
-9.94%

Equity Sectors*

  • Basic Materials

    -3.56%

  • Communication Services

    +0.11%

  • Consumer Cyclical

    -0.57%

  • Consumer Defensive

    -0.30%

  • Energy

    +0.19%

  • Financial Services

    -0.06%

  • Healthcare

    -0.37%

  • Industrials

    -0.81%

  • Real Estate

    -0.85%

  • Technology

    -0.12%

  • Utilities

    -0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…